Investigational drug · Phase 2
AP31969
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atrial Fibrillation (AF).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "AP31969"
First trial start
2025
Oct 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AP31969", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atrial Fibrillation (AF)
Approved drugs for the same conditions: Atrial fibrillation · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AP31969" as an intervention, largest first.
- Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial FibrillationPivotal-lookingRecruiting
Acesion PharmaIndustry
NCT07267949 · 200 participants (planned) · Start Oct 22, 2025 · Primary completion May 2027
Drug: AP31969; Placebo · For: Atrial Fibrillation (AF)
Sites: Plovdiv, Bulgaria; Sofia, Bulgaria; Varna, Bulgaria · 46 sites in all
Acesion PharmaIndustry
NCT06066099 · 92 participants · Start Oct 4, 2023 · Primary completion Mar 14, 2025
Drug: AP31969; Placebo · For: Healthy Volunteers
Sites: Groningen, Netherlands
Acesion PharmaIndustry
NCT07449390 · 28 participants · Start Apr 1, 2026 · Primary completion May 9, 2026
Drug: AP31969; Carbamazepine and 1 more · For: Healthy Participants
Sites: San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
- The present and future of antiarrhythmic drugs.
Nistor S, Dan GA · JRSM Cardiovasc Dis 2026
Also in development for Atrial Fibrillation (AF)
- REGN7508CenvacibartPhase 312 trials
Regeneron · Atrial Fibrillation (AF), Venous Thromboembolism (VTE), Venous Thromboembolism
- REGN9933amrecibartPhase 35 trials
Regeneron · Atrial Fibrillation (AF), Peripheral Artery Disease (PAD), Venous Thromboembolism (VTE)
- AbelacimabMAA868Phase 33 trials
Anthos Therapeutics, Inc. · Atrial Fibrillation (AF), Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.